The selection of a subset of the clinical trials based on the Phase and Status of a trial is explained in Section 2.1. All entities of interest (drugs, bioactivities, etc.) are not common across the databases. In other words, there is steady depletion in the number of trials that can be used in the data set since the corresponding feature necessary for this study may not be present across multiple databases (For example, a particular drug associated with a trial may be found in DrugBank, but not in CTD. In which case, the clinical trial record is dropped). As presented in Section S6 of Supporting Information, the final number of data points is an aggregate result of applying exclusion conditions and removing non-mappable points during data integration.